8-K: Treace Medical Reports Preliminary Q4, Full-Year 2025 Revenue

Treace Medical Concepts announced preliminary unaudited Q4 and full-year 2025 revenue, with full-year results meeting guidance despite a Q4 decline.

Summary

• Preliminary unaudited revenue for the fourth quarter of 2025 was between $62.1 million and $62.5 million, representing an approximate 9% decrease at the midpoint compared to Q4 2024.
• Preliminary unaudited full-year 2025 revenue was between $212.3 million and $212.7 million, an approximate 2% increase at the midpoint over the prior year.
• Full-year 2025 revenue was in-line with the previously provided guidance range of $211 million to $213 million.
• The company added approximately 202 new active surgeons in full-year 2025, ending the year with approximately 3,337 active surgeons, a 6% increase year-over-year.
• Approximately 33% of the estimated 10,000 U.S. surgeons performing bunion surgery used Treace systems in 2025.
• The company anticipates continued positive procedure volume growth in 2026, but also expects headwinds from broader economic conditions, softer consumer sentiment, and a product mix shift.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While Q4 revenue saw a decline and 2026 faces economic headwinds, the full-year revenue met guidance, surgeon adoption is growing, and the company maintains a strong market position with a robust product pipeline. The long-term strategic focus on market penetration and profitability is encouraging.

Positives

• Full-year 2025 revenue met the company's previously provided guidance range of $211 million to $213 million.
• Active surgeon additions for full-year 2025 totaled approximately 202, increasing the total active surgeon base by 6% to 3,337.
• Surgeon adoption of the expanded suite of 3D bunion technologies drove mid-single-digit case volume growth in Q4 2025.
• The company maintains a leading position in the bunion market and is focused on expanding its market share and improving profitability.
• A strong R&D pipeline is in place for 2026 and beyond, including new technologies like Lapiplasty Lightning, IntelliGuide PSI, and SpeedTMT.
• The company is expanding its offerings to build wallet share with products like Nanoplasty, Percuplasty, and various complementary biologics and sterile instruments.

Negatives

• Preliminary Q4 2025 revenue decreased by approximately 9% at the midpoint compared to the same period in 2024.
• The company anticipates continued headwinds in 2026 related to broader economic conditions and softer consumer sentiment.
• A product mix shift is expected to impact 2026 dynamics.
• The preliminary unaudited financial information is subject to change pending completion of internal closing processes and external auditing procedures.

Risks

• Actual results may differ materially from forward-looking statements due to numerous risks and uncertainties.
• Challenges in the current market environment, including increased competition and evolving surgeon and patient preferences for minimally invasive bunion solutions, could impact performance.
• Changes in tariff and trade policies, economic uncertainty, or soft consumer sentiment pose potential risks.
• The ability to effectively respond to and mitigate the impact of market challenges is crucial.
• The company's preliminary, unaudited results are subject to change and should not be unduly relied upon as they may differ materially from actual results.

Future Outlook

The company is not issuing full-year 2026 guidance at this time but anticipates continued positive procedure volume growth. However, it expects headwinds related to broader economic conditions, softer consumer sentiment, and a product mix shift. Full 2026 financial guidance is planned to be provided during the Q4 2025 earnings conference call on February 26, 2026.

Management Comments

• "Despite top-line headwinds, we are encouraged by our fourth-quarter progress. Surgeon adoption of our expanded suite of 3D bunion technologies again drove midsingle-digit case volume growth in the quarter."
• "Supported by our dedicated, bunion-focused sales force, these technologies position us to further penetrate the bunion market and expand our surgeon customer base."
• "We maintain a leading position in the bunion market and remain focused on expanding our share of the bunion procedure market, improving profitability, and delivering long-term value to shareholders."

Industry Context

Treace Medical Concepts operates in the medical technology sector, specifically focusing on the surgical treatment of bunions and related midfoot deformities. The company highlights the bunion market as the largest and most underpenetrated segment in foot and ankle, with an estimated 67 million Americans affected and 1.1 million annual surgical candidates, representing a $5B+ U.S. market opportunity. The company is driving a fundamental shift towards 3D bunion correction and expanding into minimally invasive osteotomy procedures, aligning with evolving surgeon and patient preferences.

Comparison to Industry Standards

• The company claims a leading position in the bunion market, which is the largest and most underpenetrated segment in foot and ankle.
• Approximately 33% of the estimated 10,000 U.S. surgeons performing bunion surgery used Treace bunion systems in 2025, indicating significant market penetration.
• The Lapiplasty procedure is presented as the 'Gold Standard for 3-Plane Correction' and is the only commercial surgical bunion system supported by 4-year multicenter, prospective data, demonstrating differentiated clinical outcomes compared to general industry offerings.
• The company's 5-year CAGR in active surgeons (2020-2025) is 21%, suggesting strong growth in its surgeon base relative to the overall market.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through market share expansion and improved profitability, but short-term concerns due to Q4 revenue decline and anticipated 2026 headwinds.
• Surgeons: Access to an expanded suite of 3D bunion technologies, including minimally invasive options, and continued education and training.
• Patients: Benefit from advanced 3D bunion correction systems, including options for early weight-bearing and low recurrence rates, and increased access to minimally invasive procedures.
• Employees: Continued growth and expansion of the sales force and R&D efforts.

Next Steps

• Provide 2026 financial guidance during the Q4 2025 earnings conference call on Thursday, February 26, 2026.
• Continue to expand the product portfolio with new technologies like Lapiplasty Lightning, IntelliGuide PSI, and SpeedTMT in 2026.
• Accelerate bunion procedure volume growth and expand the surgeon customer base.
• Focus on improving profitability through operating expense leverage and management.

Key Dates

Recommendation

The company's full-year 2025 revenue met guidance, demonstrating execution despite a challenging Q4. While the Q4 revenue decline and anticipated 2026 headwinds (economic conditions, consumer sentiment, product mix) are concerns, Treace maintains a strong leadership position in a large, underpenetrated market. Its expanding product portfolio, growing active surgeon base, and commitment to profitability suggest long-term potential. However, the immediate future presents uncertainties, warranting a 'hold' until more clarity on 2026 guidance and the impact of headwinds is available.

Keywords

bunion surgery, medical technology, Lapiplasty, foot and ankle, orthopedics, minimally invasive surgery, financial results, revenue, surgeon adoption, TMCI